retatrutide study results phase 3 trials Looking forward to when #retatrutide's trial will become available. There are Retatrutide for weight loss: Study

R et al., 2022)

NICE approved semaglutide (Wegovy) for weight management in specialist NHS weight management services in 2023 (TA875), but availability is limited to patients with: BMI 35 kg/m with at least one weight-related comorbidity, or BMI 30 kg/m with exceptional circumstances Lower BMI thresholds apply for people from some minority ethnic groups (typically 27.5 kg/m) Participation in a specialist weight management programme Treatment limited to a maximum of 2 years Access varies by region due to local integrated care board (ICB) implementation decisions and limited NHS specialist service capacity

in a new tab Collins L

With pervasive stress and the prevalence of nutritionally deficient fast-food options around every corner, losing weight and keeping it off is challenging in today's day and age

Zepbound , containing the active ingredient tirzepatide , is a newer medication that acts on both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors

Report suspected illegal online sales or unlicensed supply to the MHRA via gov.uk/report-problem-medicine-medical-device